Auto-antibody Dosage From Blood Spots for Diagnosis of Type 1 Diabetes and Celiace Disease

Launched by MEYER CHILDREN'S HOSPITAL IRCCS · Feb 25, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how to better detect two conditions: type 1 diabetes and celiac disease, especially in children. Early diagnosis of these diseases is important because it can lead to timely treatment, which helps prevent serious health issues. The study will compare results from two different ways of testing for specific antibodies in the blood—one method involves testing blood drops collected on a card, while the other uses serum, which is the liquid part of blood. The goal is to see how well these two testing methods agree with each other and to find out how acceptable and practical this screening process is for families.

Children aged 2 to 13 who either have been diagnosed with type 1 diabetes or celiac disease, or who do not have either condition, might be eligible to participate. Families who join the study will work with local pediatricians and will help researchers understand how effective and easy this new testing method is for identifying these conditions in young patients. There are no specific exclusions for participants, making it an inclusive opportunity for many families.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 2-13 years
• • Patients with a confirmed diagnosis of type 1 diabetes or celiac disease (positive controls) and children who do not have type 1 diabetes or celiac disease or autoantibodies associated with these pathologies (controls)
• • Obtained informed consent
• Exclusion Criteria:
• • none